A Step Closer to Predicting Progression After Bacillus Calmette-Guérin Immunotherapy in High-risk Non–muscle-invasive Bladder Cancer

Treatment-naïve tumors from patients who then experience recurrence or progression after bacillus Calmette-Guérin (BCG) therapy exhibit elevated expression of genes associated with basal differentiation and immune suppression. Three tumor molecular subtypes have been associates with distinct clinical outcomes and will allow early identification of patients unlikely to respond to BCG immunotherapy.